Literature DB >> 17973644

In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.

A Aloulou1, D Puccinelli, J Sarles, R Laugier, Y Leblond, F Carrière.   

Abstract

BACKGROUND: Various pancreatic enzyme preparations are used for the treatment of pancreatic insufficiency but their bioequivalence is often unknown. AIM: To determine in vitro the pH-dependent release and acid resistance of enzymes from three commercially available pancreatin capsules, two containing enteric-coated (Creon 25000; Eurobiol 25000) and one uncoated (Eurobiol 12500) microspheres.
METHODS: Dissolution experiments were performed at pH values ranging from 4.0 to 5.8. Lipase, chymotrypsin and amylase activities were measured in the solution as a function of time.
RESULTS: Eurobiol 25000 started to release its enzymes significantly at pH 5.0 (t(1/2) = 71 min), whereas the enzymes from Creon 25000 were only released at higher pH value (5.4; t(1/2) = 49.2 min). Unlike chymotrypsin, lipase and amylase were highly sensitive to acidic conditions at the lowest pH values tested. Both enzymes were also found to be sensitive to proteolytic inactivation at the highest pH values tested. Overall, Eurobiol 25000 released higher amounts of active amylase and lipase than Creon 25000 at the pH values usually found in duodenal contents. The uncoated Eurobiol 12500 preparation was, however, the only one that could immediately release rather high levels of active chymotrypsin and lipase at low pH (4.5).
CONCLUSION: These findings suggest that pH-sensitive enteric-coated pancreatin products containing similar amounts of enzymes might not be bioequivalent depending on the pH of duodenal contents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17973644     DOI: 10.1111/j.1365-2036.2007.03563.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

Review 1.  Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.

Authors:  Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2013-11-02       Impact factor: 4.200

Review 2.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 3.  Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain.

Authors:  Gyanprakash A Ketwaroo; David Y Graham
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats.

Authors:  Ahmed Aloulou; Khaled Hamden; Dhouha Elloumi; Madiha Bou Ali; Khaoula Hargafi; Bassem Jaouadi; Fatma Ayadi; Abdelfattah Elfeki; Emna Ammar
Journal:  BMC Complement Altern Med       Date:  2012-05-16       Impact factor: 3.659

5.  Enzyme replacement therapy for pancreatic insufficiency: present and future.

Authors:  Aaron Fieker; Jessica Philpott; Martine Armand
Journal:  Clin Exp Gastroenterol       Date:  2011-05-04

6.  Practical guide to exocrine pancreatic insufficiency - Breaking the myths.

Authors:  Maarten R Struyvenberg; Camilia R Martin; Steven D Freedman
Journal:  BMC Med       Date:  2017-02-10       Impact factor: 8.775

7.  A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis.

Authors:  Joaquim Calvo-Lerma; Victoria Fornés-Ferrer; Irene Peinado; Ana Heredia; Carmen Ribes-Koninckx; Ana Andrés
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 8.  Pancreatic exocrine insufficiency after pancreaticoduodenectomy: Current evidence and management.

Authors:  Adithya M Pathanki; Joseph A Attard; Elizabeth Bradley; Sarah Powell-Brett; Bobby V M Dasari; John R Isaac; Keith J Roberts; Nikolaos A Chatzizacharias
Journal:  World J Gastrointest Pathophysiol       Date:  2020-04-12

9.  Individualized pharmaceutical care for a patient after pancreaticoduodenectomy with trypsin replacement nutritional therapy: A case report.

Authors:  Song Zhang; Qin Tan; Hanjun He
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.